They bind to GLP-1 receptors in the body, producing effects similar to GLP-1 but in a more sustained manner
Liraglutide vs Semaglutide: The Molecular Difference Liraglutide (Saxenda): First-generation GLP-1 agonist for weight loss Approximately 97% amino acid similarity to natural GLP-1 Half-life of approximately 13 hours Requires daily injection to maintain blood levels Semaglutide (Ozempic, Wegovy): Second-generation GLP-1 agonist Modified structure for greater potency and longer action Half-life of approximately 7 days Weekly injection maintains stable blood levels The structural modifications in semaglutide make it bind more effectively to GLP-1 receptors and resist breakdown longer
There was one report each of brown urine, cellulitis, conjunctivitis, cyst/nodule formation on thyroid, decrease bilirubin, elevated cholesterol and triglycerides, hematochezia, increased intraocular pressure, irregular menstruation, keloid scar formation, nausea, stunted growth, swelling, and a side effect of unknown type (0.5%)
buffer: 22.7% 3.6%, n = 13
Although the actions of GLP-1 on the beta-cell are preserved yet modestly diminished in T2DM, the diabetic alpha-cell retains near normal responsivity to low dose GLP-1 infusion, with inhibition of glucagon secretion seen to a similar extent in diabetic vs
Patients should never initiate or combine these medications without explicit medical guidance, as doing so may increase the risk of side effects or complicate existing health conditions
